Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

Clinical Gastroenterology and Hepatology(2020)10.1016/j.cgh.2020.01.008Source: DataRank Database

First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis is a research paper published in Clinical Gastroenterology and Hepatology (2020). On theSindex it has a DataRank of 0. It has been cited 383 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access383 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 37.63)OA: greenTopics (66)Linked Datasets (10)DataCite Reuse (10)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Mohammad Hassan Murad ORCID,Mathurin Fuméry ORCID,Parambir S. Dulai ORCID,William J. Sandborn ORCID,Siddharth Singh ORCID

Live enrichment

PubMed:31945470 PMC:PMC8022894 OpenAlex:https://openalex.org/W3000124921

Crohn's and Colitis Foundation

Grant: 404614

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: K23DK117058

American College of Gastroenterology

Grant: 144271

NIDDK NIH HHS

Grant: P30 DK120515

National Institutes of Health

Grant: 5K23DK117058-05

Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel Diseases

National Institutes of Health

AbbVie

Prometheus

Celgene

Pfizer

Shire

Gilead Sciences

Janssen Biotech

Takeda Pharmaceuticals U.S.A.

FWCI

37.63

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8022894

publisherhttps://api.elsevier.com/content/article/PII:S1542356520300446?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1542356520300446?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cgh.2020.01.008

Fields of Study

Inflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesClostridium difficile and Clostridium perfringens research03 medical and health sciences0302 clinical medicineAdalimumabAdultColitis, UlcerativeHumansInfliximabUstekinumab

MeSH Terms

AdalimumabInfliximabUstekinumabNetwork Meta-AnalysisNetwork Meta-Analysis as TopicAdultColitis, UlcerativeHumans

Keywords

MedicineUlcerative colitisInternal medicineMeta-analysisGastroenterologyMEDLINEDiseaseGradeInflammatory Bowel DiseasePharmacotherapyUcComparative EfficacyAdultUlcerative (mesh)Adalimumab (mesh)Clinical SciencesClinical Trials and Supportive ActivitiesNetwork Meta-AnalysisClinical Trials and Supportive Activities (rcdc)610UlcerativeAutoimmune DiseaseClinical Research (rcdc)Clinical ResearchInflammatory Bowel Disease (rcdc)1103 Clinical Sciences (for)Humans32 Biomedical and Clinical Sciences (for-2020)3202 Clinical Sciences (for-2020)Autoimmune Disease (rcdc)Humans (mesh)6.1 Pharmaceuticals (hrcs-rac)Biomedical and Clinical SciencesGastroenterology & HepatologyAdalimumab600ColitisUstekinumab (mesh)Infliximab6.1 PharmaceuticalsInfliximab (mesh)Adult (mesh)Colitis, UlcerativeUstekinumabGastroenterology & Hepatology (science-metrix)Digestive DiseasesDigestive Diseases (rcdc)

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

10.6084/m9.figshare.15102556.v1figshare

Additional file 1 of Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

10.6084/m9.figshare.15102556figshare

Additional file 2 of Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

10.6084/m9.figshare.15102559.v1figshare

Additional file 2 of Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

10.6084/m9.figshare.15102559figshare

Additional file 1 of Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

10.6084/m9.figshare.20033112.v1figshare

Additional file 1 of Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

10.6084/m9.figshare.20033112figshare

Additional file 4 of Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

10.6084/m9.figshare.15102565.v1figshare

Additional file 4 of Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

10.6084/m9.figshare.15102565figshare

Additional file 3 of Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

10.6084/m9.figshare.15102562.v1figshare

Additional file 3 of Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

10.6084/m9.figshare.15102562figshare